39th World Seminar on Pharmacology & Drug Development
  • Follow

Accepted Abstracts

Cushing Syndrome: A Review and Its Treatment by Emerging Molecule Osilodrostat

Akhilesh Kumar Singh*, Vishal, Vaneet Singh Thakur, Aarti Devi and Dayanidhi Pandey
Aishwarya Group, India.

Citation: Singh AK (2023) Cushing Syndrome: A Review and Its Treatment by Emerging Molecule Osilodrostat. SciTech Central Pharma 2023.

Received: March 06, 2023         Accepted: March 09, 2023         Published: March 09, 2023

Abstract

Cushing syndrome is mainly the Hypercortisolism state in our body which is due to many factors like in appropriate exposure of Glucocorticoids. It can be endogenous as well as exogenous depending upon the cause and responsible factors. Screening of Cushing syndrome includes procedures like UFC test, Low Dose DST, Low dose salivary cortisol levels. Diagnosis of the Syndrome involves the MRI of Pituitary gland, Overnight Dexamethasone test. Some of complications arising from this syndrome are excessive weight gain, Hypertension, Diabetes mellitus, decreased immune response, depression and Depression. Treatment of Cushing syndrome is done by various therapies like Pituitary surgery, adrenal surgery and medical  treatment which involve use of various drugs for treatment. Osilodrostat has shown veryimpressive results in treatment of Cushing Syndrome as compared to other available options of drugs like Ketoconazole and Metyrapone. Further studies are to be done on Osilodrostat toconclude a perfect and permanent treatment of Cushing Syndrome.
Keywords: Cushing syndrome, Hypercortisolism, Glucocorticoids, Diabetes mellitus, Dexamethasone, Ketoconazole, Osilodrostat